Clinical Trials Logo

Clinical Trial Summary

Aseptic abscess syndrome (AA) is a rare entity characterized by the occurrence of deep abscesses with no germ found. Antibiotic therapy is ineffective and they are sensitive to anti-inflammatory treatment with corticosteroids. Gut microbiota is important for the development of the immune system. In Crohn's disease which is frequently associated with AA syndrome, dysbiosis is found but could also be involved in the immune response at a distance from the gut. Stool, blood, saliva and urine samples will be taken from the patients included and their controls in the centers where they are followed. These biological samples will be transported to Clermont Ferrand using the same procedure (transporter and dry ice) where the following analyses will be performed: microbiota on stool and saliva, short chain fatty acids on stool and lymphocyte study on blood.


Clinical Trial Description

- Included patients will be adult patients meeting the diagnostic criteria for aseptic abscess syndrome described by André et al. - Controls will be adults without aseptic abscess syndrome living in the same environment as the patients, whether related to the patient or not. Patients and controls must be able to provide informed consent and be affiliated with the French Social Security system. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05537909
Study type Interventional
Source University Hospital, Clermont-Ferrand
Contact Lise Laclautre, PharmD
Phone 04 73 754 963
Email promo_interne_drci@chu-clermontferrand.fr
Status Recruiting
Phase N/A
Start date September 7, 2021
Completion date December 31, 2024